Novartis Vanrafia Phase III Data Show Slowing of Kidney Function Decline in IgA Nephropathy
Novartis announced final Phase III ALIGN results showing Vanrafia slowed kidney function decline in adults with IgA nephropathy, supporting planned submissions for traditional approval in 2026 following accelerated approvals in the U.S. and China in 2025.